CPT2 immunoreactivity was weak in NMGs (Figure 3A) and increased in 72% of G1 carcinomas, with strong and diffuse cytoplasmic CPT2 immunostaining (Figure 3B). This evidence concerns the gene CPT2 and carcinoma.